share_log

T2 Biosystems | SC 13D: Statement of acquisition of beneficial ownership by individuals-Nathan D. Hukill(46.68%),CR Group L.P.(46.68%), etc.

T2 Biosystems | SC 13D: Statement of acquisition of beneficial ownership by individuals-Nathan D. Hukill(46.68%),CR Group L.P.(46.68%), etc.

T2 Biosystems | SC 13D：超過5%持股股東披露文件-Nathan D. Hukill(46.68%),CR Group L.P.(46.68%)等
美股SEC公告 ·  04/19 13:36

牛牛AI助理已提取核心訊息

On April 12, 2024, a significant change in ownership was reported for T2 Biosystems, Inc., a company specializing in medical diagnostic technology. A group led by Nathan D. Hukill, including CR Group L.P. and various CRG Partners funds, filed a Schedule 13D with the SEC, indicating they had collectively acquired a 46.68% beneficial ownership in T2 Biosystems. This acquisition was the result of a debt cancellation agreement in exchange for common stock, which was previously reported in a Schedule 13G filing. The group's beneficial ownership crossed the 20% threshold, triggering the Schedule 13D filing requirement. The shares were acquired for investment purposes with the intention of increasing the value of their investment in T2 Biosystems. The group may consider acquiring additional shares or disposing of their holdings in the future. The principal business of the group is healthcare-focused investments, and they have not been involved in any legal proceedings related to securities laws in the past five years.
On April 12, 2024, a significant change in ownership was reported for T2 Biosystems, Inc., a company specializing in medical diagnostic technology. A group led by Nathan D. Hukill, including CR Group L.P. and various CRG Partners funds, filed a Schedule 13D with the SEC, indicating they had collectively acquired a 46.68% beneficial ownership in T2 Biosystems. This acquisition was the result of a debt cancellation agreement in exchange for common stock, which was previously reported in a Schedule 13G filing. The group's beneficial ownership crossed the 20% threshold, triggering the Schedule 13D filing requirement. The shares were acquired for investment purposes with the intention of increasing the value of their investment in T2 Biosystems. The group may consider acquiring additional shares or disposing of their holdings in the future. The principal business of the group is healthcare-focused investments, and they have not been involved in any legal proceedings related to securities laws in the past five years.
2024年4月12日，據報道，專門從事醫療診斷技術的公司T2 Biosystems, Inc. 的所有權發生了重大變化。由內森·哈基爾領導的一個集團，包括CR集團有限責任公司和CRG Partners的各種基金，向美國證券交易委員會提交了附表13D，表示他們共同收購了T2 Biosystems4％的受益所有權。此次收購是以普通股換取債務取消協議的結果，該協議此前已在附表13G的文件中進行了報告。該集團的實益所有權超過了20％的門檻，觸發了附表13D的申報要求。收購這些股票是出於投資目的，目的是增加他們對T2 Biosystems的投資價值。該集團將來可能會考慮收購更多股份或出售其持有的股份。該集團的主要業務是以醫療保健爲重點的投資，在過去五年中，他們沒有參與任何與證券法有關的法律訴訟。
2024年4月12日，據報道，專門從事醫療診斷技術的公司T2 Biosystems, Inc. 的所有權發生了重大變化。由內森·哈基爾領導的一個集團，包括CR集團有限責任公司和CRG Partners的各種基金，向美國證券交易委員會提交了附表13D，表示他們共同收購了T2 Biosystems4％的受益所有權。此次收購是以普通股換取債務取消協議的結果，該協議此前已在附表13G的文件中進行了報告。該集團的實益所有權超過了20％的門檻，觸發了附表13D的申報要求。收購這些股票是出於投資目的，目的是增加他們對T2 Biosystems的投資價值。該集團將來可能會考慮收購更多股份或出售其持有的股份。該集團的主要業務是以醫療保健爲重點的投資，在過去五年中，他們沒有參與任何與證券法有關的法律訴訟。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間